Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Change in Cash (2022 - 2025)

Stoke Therapeutics has reported Change in Cash over the past 4 years, most recently at $826000.0 for Q4 2025.

  • For Q4 2025, Change in Cash rose 103.79% year-over-year to $826000.0; the TTM value through Dec 2025 reached -$43.8 million, up 30.67%, while the annual FY2025 figure was -$43.8 million, 30.67% up from the prior year.
  • Change in Cash for Q4 2025 was $826000.0 at Stoke Therapeutics, up from -$18.2 million in the prior quarter.
  • Over five years, Change in Cash peaked at $146.8 million in Q1 2025 and troughed at -$173.3 million in Q2 2025.
  • A 4-year average of -$3.8 million and a median of -$961500.0 in 2022 define the central range for Change in Cash.
  • Biggest five-year swings in Change in Cash: crashed 1986.41% in 2024 and later surged 1241.69% in 2025.
  • Year by year, Change in Cash stood at $160000.0 in 2022, then surged by 815.62% to $1.5 million in 2023, then crashed by 1588.46% to -$21.8 million in 2024, then skyrocketed by 103.79% to $826000.0 in 2025.
  • Business Quant data shows Change in Cash for STOK at $826000.0 in Q4 2025, -$18.2 million in Q3 2025, and -$173.3 million in Q2 2025.